Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity

Diabetologia
C F DeaconJ J Holst

Abstract

Glucagon-like peptide 1 (GLP-1) has great potential in diabetes therapy due to its glucose-dependent stimulation of insulin secretion, but this is limited by its rapid degradation, primarily by dipeptidyl peptidase IV. Four analogues, N-terminally substituted with threonine, glycine, serine or alpha-aminoisobutyric acid, were synthesised and tested for metabolic stability. All were more resistant to dipeptidyl peptidase IV in porcine plasma in vitro, ranging from a t1/2 of 159 min (Gly8 analogue) to undetectable degradation after 6 h (Aib8 analogue; t1/2 for GLP-1 (7-36) amide, 28 min). During i. v. infusion in anaesthetised pigs, over 50% of each analogue remained undegraded compared to 22.7 % for GLP-1 (7-36) amide. In vivo, analogues had longer N-terminal t1/2 (intact peptides: means, 3.3-3.9 min) than GLP-1 (7-36) amide (0.9 min; p < 0.01), but these did not exceed the C-terminal t1/2 (intact plus metabolite: analogues, 3.5-4.4 min; GLP-1 (7-36) amide, 4.1 min). Analogues were assessed for receptor binding using a cell line expressing the cloned receptor, and for ability to stimulate insulin or inhibit glucagon secretion from the isolated perfused porcine pancreas. All bound to the receptor, but only the Aib8 and Gly8 analo...Continue Reading

Citations

Dec 7, 2002·Diabetes/metabolism Research and Reviews·Jens Juul Holst
Apr 20, 2006·Amino Acids·M Werle, A Bernkop-Schnürch
Sep 4, 2009·Applied Biochemistry and Biotechnology·Mingming GaoWenbing Yao
Dec 22, 2011·Annals of Nuclear Medicine·Ayahisa WatanabeYuji Kuge
Mar 29, 2005·Journal of the American Society for Mass Spectrometry·Kim F HaselmannRoman A Zubarev
May 15, 2002·European Journal of Pharmacology·Juris J MeierMichael A Nauck
Sep 17, 2002·European Journal of Pharmacology·Ulla RibelLotte Bjerre Knudsen
Dec 9, 2000·Regulatory Peptides·J A PospisilikH Demuth
Apr 1, 1999·Regulatory Peptides·E G SiegelW E Schmidt
Feb 15, 2000·Regulatory Peptides·B GallwitzW E Schmidt
Feb 15, 2003·Domestic Animal Endocrinology·D G BurrinX Guan
Feb 1, 2012·Nature Reviews. Cardiology·Jacob SivertsenTina Vilsbøll
Jul 25, 2009·Antioxidants & Redox Signaling·Yasuo IdoJoseph R Williamson
Jan 21, 2012·Nuclear Medicine Communications·Yifan Zhang, Wengen Chen
May 9, 2013·Nuclear Medicine Communications·Haifei WuYifan Zhang
Jun 6, 2012·Experimental Diabetes Research·Francis S Willard, Kyle W Sloop
May 14, 2009·Vascular Health and Risk Management·Carolyn F Deacon
Mar 16, 2005·Treatments in Endocrinology·Laurie L Baggio, Daniel J Drucker
Mar 19, 2003·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Juris J MeierMichael A Nauck
Mar 19, 2013·Future Medicinal Chemistry·Ahmed Mehanna
Jul 5, 2005·Expert Opinion on Investigational Drugs·J J Holst
Jul 12, 2005·Expert Opinion on Investigational Drugs·Octaviano A RogesAthena Philis-Tsimikas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.